BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

442 results

Results per page: 10 20 30

Information Letter on Lynparza® 50 mg hard capsules (active ingredient olaparib): discontinuation of production at the end of 2021 PDF, 83KB, File is accessible Date: 29. June 2021 Topics: Pharmakovigilanz Aktuelles Type: Direct Healthcare Professional Communication

Active substance: olaparib

AstraZeneca informs that the production of Lynparza® 50 mg hard capsules (active ingredient: olaparib) will be discontinued at the end of 2021.

Direct Healthcare Professional Communication (DHPC) on Minprostin®, Prepidil®, Propess® (dinoprostone-containing drugs): updates to product information on risk reduction of uterine hyperstimulation, uterine rupture, and fetal/neonatal death. PDF, 295KB, File is accessible Date: 28. June 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dinoprostone

The product information for dinoprostone-containing drugs (Minprostin®, Prepidil®, Propess®) is updated.

Information Letter on INOmax® 800 ppm mol/mol, gas for medical use: difficulties with closing cylinder valves after use PDF, 127KB, File is accessible Date: 18. June 2021 Topics: Pharmakovigilanz Aktuelles Type: Direct Healthcare Professional Communication

Active substance: Nitric Oxide

The company Linde Healthcare AB informs that INOmax® cylinders that are not completely empty cannot be closed properly after opening.

Direct Healthcare Professional Communication (DHPC) on Amiodaron-hameln 50 mg/ml Concentrate for Solution for Injection/Infusion: visual inspection required due to possible crystallization PDF, 164KB, File is accessible Date: 17. June 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: amiodarone

The company Hameln Pharma GmbH would like to inform that there is an increased potential for crystallization in ampoules.

Direct Healthcare Professional Communication (DHPC) on Venclyxto® (venetoclax) film coated tablets: updated recommendations on tumour lysis syndrome (TLS) in CLL patients PDF, 110KB, File is accessible Date: 10. June 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: venetoclax

AbbVie in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you of fatal cases of TLS.

Direct Healthcare Professional Communication (DHPC) on Azazitidin 25 mg/ml: letter to healthcare professionals about potential risk of incorrect reconstitution (medication error) PDF, 257KB, File is accessible Date: 20. May 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: azacitidine

The marketing authorization holders of Azacitidin 25 mg/ml would like to inform in agreement with the Federal Institute for Drugs and Medical Devices (BfArM) of the new 150 mg azacitidine presentation on the market and the potential risk of …

Direct Healthcare Professional Communication (DHPC) on Eylea® 40 mg/ml (aflibercept solution for intravitreal injection): higher risk of intraocular pressure increase with the pre-filled syringe PDF, 468KB, File is accessible Date: 15. April 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: aflibercept

Bayer, in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), would like to inform of cases of increased intraocular pressure.

Direct Healthcare Professional Communication (DHPC) on ▼Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF— alpha inhibitors PDF, 322KB, File is accessible Date: 25. March 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: tofacitinib

Preliminary results from a clinical trial suggest an increased risk of serious cardiovascular events and malignancies (other than NMSC) with the use of tofacitinib compared to TNF-alpha inhibitors.

Direct Healthcare Professional Communication (DHPC) on Cabazitaxel Accord® 20 mg/ml concentrate for solution for infusion: risk of medication errors and confusion with Jevtana® (60 mg/1.5 ml) concentrate and solvent for solution for infusion PDF, 244KB, File is accessible Date: 09. March 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: cabazitaxel

Accord Healthcare S.L.U., Spain, in coordination with the European Medicines Agency (EMA) and the German Federal Institute for Drugs and Medical Devices (BfArM), would like to inform about the risk for the occurrence of medication errors due …

Direct Healthcare Professional Communication (DHPC) on Lojuxta® (Lomitapide): liver function monitoring and contraindication during pregnancy PDF, 271KB, File is accessible Date: 17. February 2021 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: lomitapide

The company Amryt Pharmaceuticals DAC, in coordination with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), reminds that lomitapide is contraindicated in patients with impaired liver …